Auour Investments LLC Takes $3.30 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Auour Investments LLC acquired a new stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 250,000 shares of the company's stock, valued at approximately $3,302,000. Neumora Therapeutics accounts for about 1.2% of Auour Investments LLC's holdings, making the stock its 26th biggest position. Auour Investments LLC owned about 0.16% of Neumora Therapeutics at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Ballentine Partners LLC purchased a new position in shares of Neumora Therapeutics during the third quarter valued at approximately $178,000. Clarius Group LLC purchased a new position in Neumora Therapeutics during the third quarter valued at $224,000. Handelsbanken Fonder AB boosted its holdings in Neumora Therapeutics by 35.0% in the third quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company's stock worth $351,000 after acquiring an additional 6,900 shares in the last quarter. Quarry LP purchased a new stake in shares of Neumora Therapeutics in the second quarter worth $98,000. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Neumora Therapeutics by 79.5% during the second quarter. The Manufacturers Life Insurance Company now owns 111,828 shares of the company's stock valued at $1,099,000 after acquiring an additional 49,527 shares in the last quarter. Institutional investors own 47.65% of the company's stock.

Neumora Therapeutics Stock Up 1.7 %

NMRA traded up $0.20 during midday trading on Tuesday, reaching $11.91. The company had a trading volume of 1,421,880 shares, compared to its average volume of 712,174. Neumora Therapeutics, Inc. has a 1 year low of $8.33 and a 1 year high of $21.00. The company has a market cap of $1.91 billion, a P/E ratio of -4.57 and a beta of 3.92. The business has a 50-day moving average of $12.92 and a two-hundred day moving average of $11.29.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.37). On average, equities research analysts predict that Neumora Therapeutics, Inc. will post -1.48 EPS for the current year.

Insider Transactions at Neumora Therapeutics

In related news, insider Robert A. Lenz sold 5,563 shares of Neumora Therapeutics stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the transaction, the insider now owns 322,966 shares in the company, valued at approximately $4,847,719.66. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Robert A. Lenz sold 5,563 shares of the stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the sale, the insider now owns 322,966 shares in the company, valued at approximately $4,847,719.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Robert A. Lenz sold 30,788 shares of the business's stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the transaction, the insider now directly owns 339,205 shares in the company, valued at approximately $4,006,011.05. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 110,538 shares of company stock valued at $1,390,513 over the last three months. Corporate insiders own 26.40% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on NMRA. Royal Bank of Canada restated an "outperform" rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a report on Wednesday, September 4th. Needham & Company LLC reiterated a "buy" rating and set a $23.00 target price on shares of Neumora Therapeutics in a research note on Friday, October 18th. HC Wainwright started coverage on Neumora Therapeutics in a research note on Tuesday, October 1st. They issued a "buy" rating and a $30.00 price target on the stock. JPMorgan Chase & Co. lowered Neumora Therapeutics from an "overweight" rating to a "neutral" rating and cut their price objective for the stock from $18.00 to $15.00 in a report on Tuesday. Finally, Mizuho assumed coverage on Neumora Therapeutics in a report on Monday, July 8th. They issued an "outperform" rating and a $20.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $21.67.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.